Tennor Therapeutics (Suzhou) Ltd

Company Profile

• Business description

  Tennor Therapeutics (Suzhou) Ltd is a near-commercial stage biotechnology company. Along with its subsidiaries, the company is principally engaged in the research and development as well as commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Its two core products are: rifotenizole (TNP-2198), a NME drug candidate developed for the treatment of H. pylori infection; and rifaquinone (TNP-2092 injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections.

• Contact

  218 Xinghu Street
  Unit 701, Block B7, Suzhou Industrial Park
  Suzhou Area of China (Jiangsu), BioBay
  Pilot Free Trade Zone Suzhou
  Jiangsu
  CHN

  T: +86 51286861990

  http://www.tennortherapeutics.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees